Company Active LTD

Company profile

Bigdna Ltd

UK company SC311480, incorporated on 3 November 2006.

ICENI Pharma

Bigdna Ltd is a UK company with status active founded in 2006 based in Scotland.

Company number
SC311480
Incorporated
3 Nov 2006
Companies House status
Active

Company identity

Founded / incorporated
3 November 2006

Company number SC311480

Verify at Companies House
Legal name
BIGDNA LTD
Company type
LTD
Region
Scotland
Registered address
Unknown
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

Bigdna Ltd
No active corporate controller recorded.

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
0

Company events

Reference milestones and recent Companies House filing stream events.

3 events
24 Aug
2026

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzU0MDU0NjQwNmFkaXF6a2N4

Published 24 Aug 2026 11:31

05 Aug
2026

Change Account Reference Date Company Previous Extended

Accounts Analysed

AA01 | Transaction MzUzNzIzNTQ3NWFkaXF6a2N4

Published 05 Aug 2026 16:30

03 Nov
2006

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2013
Funded years
2013, 2014
Age at first award
6 years

Projects

2014 GRD Proof of Market Lead participant

IP and commercial assessment of a novel cancer therapeutic

1 May 2014 to 31 Aug 2014

Awarded
£25,000
Total cost £43,532

BigDNA is a vaccine development company, using bacteriophages to deliver DNA vaccines. Arising as an additional output from a previous TSB SMART Proof of Concept project, the Company has identified a novel non-vaccine peptide-based cancer therapy which it believes may have significant clinical and commercial potential. This novel peptide combination has t...

2013 GRD Proof of Concept Lead participant

Optimisation of bacteriophage M13-based DNA and chimeric (DNA/ protein) vaccines

1 Feb 2013 to 31 Jan 2014

Awarded
£95,000
Total cost £161,190

Bacteriophage (phage) offer the potential to deliver both protein and DNA vaccines within the same construct. They also promise extremely rapid development and manufacturing timescales, since the DNA vaccine cassette can be synthesised to express antigens for virtually any pathogen, literally within days following sequence identification. Phage are extrem...

Product types

GRD Proof of Concept GRD Proof of Market